Iressa v BSC (Best Supportive Care) in First Line NSCLC

Summary

The purpose of the study is to determine if the addition of Iressa to Best Supportive Care treatment will increase the progression free survival of chemo-naïve, poor performance status patients, with stage IIIB or IV NSCLC.

Timeline

Start

2004-09

Primary completion

2007-02

Completion

2016-04

Drugs

Indications